You are here
From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.
A phase I trial of the anti-CD19 monoclonal antibody DI-B4 has demonstrated a highly positive safety profile, robust depletion of peripheral B cells and several partial tumour responses.Read more
We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.Read more
Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential.Read more